6. Is a pregnant or lactating female, or is planning to become pregnant during treatment and within 12 weeks after the end of treatment with ramucirumab. Women of child-bearing potential with either positive or no pregnancy test at baseline. Women of child-bearing potential or sexually active men not willing to use contraception during study and for at least 12 weeks after end of treatment with ramucirumab. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential.